Opinion

Video

Beyond EHA 2024: Promising Research in Multiple Myeloma to Watch

Author(s):

Joseph Mikhael, MD

Dr. Mikhael discusses EHA 2024 data he found particularly noteworthy to share with colleagues.

Video content above is prompted by the following question:

  • Please discuss any other data in multiple myeloma released at EHA 2024 that you find noteworthy to share with colleagues.
  • Outside of EHA 2024 what ongoing research efforts are you most excited for in the treatment and management of multiple myeloma?
  • What can we look forward to through the end of the year and beyond?
Related Videos
Leland Metheny, MD, University Hospitals Seidman Cancer Center
Jason Porter, MD, an expert on lung cancer
1 KOL is featured in this program.
1 KOL is featured in this program.
Jason Porter, MD, an expert on lung cancer
Jason Porter, MD, an expert on lung cancer
Joseph Mikhael, MD, an expert on multiple myeloma
Alfred L. Garfall, MD, an expert on multiple myeloma
Alfred L. Garfall, MD, an expert on multiple myeloma
Joseph Mikhael, MD, an expert on multiple myeloma
Related Content
Clinical trial results | Image Credit: Egor-stock.adobe.com
September 12th 2024

D-VRd Boosts MRD-Negativity in Transplant-Eligible Multiple Myeloma

Chris Ryan
The FDA approved the quadruplet regimen on July 30 for induction and consolidation therapies in patients with newly diagnoses multiple myeloma who are eligible for autologous stem cell transplant.
Leland Metheny, MD, University Hospitals Seidman Cancer Center
August 30th 2024

Triple-Target CAR T Cells: Benefits and Challenges

Maggie L. Shaw
In part 1 of our interview with Leland Metheny, MD, he explained how a new triple-target chimeric antigen receptor (CAR) T-cell therapy works in multiple myeloma.
Regeneron logo | Image credit: Casimiro – stock.adobe.com
August 21st 2024

FDA Issues CRL for Linvoseltamab in R/R Multiple Myeloma

Hayden E. Klein
The complete response letter (CRL) was issued based on a pre-approval inspection at a third-party fill/finish manufacturer.
stem cells | Image Credit: jarun011-stock.adobe.com
August 20th 2024

Second ASCT Extends Survival in Relapsed Multiple Myeloma

Maggie L. Shaw
To continue the response they experienced with a first autologous stem‐cell transplant (ASCT) for their multiple myeloma, patients in this analysis received a second ASCT, with French investigators evaluating their outcomes.
MM treatment | Image Credit: Dzmitry-stock.adobe.com
August 14th 2024

Challenges With Pomalidomide for Patients With Comorbid RRMM, CKD

Maggie L. Shaw
Patients who have comorbid relapsed/refractory multiple myeloma (RRMM) and advanced chronic kidney disease (CKD) are often excluded from clinical trials, leaving treatment gaps for these high-risk patients.
MM blood test | Image Credit: luchschenF-stock.adobe.com
August 6th 2024

Novel Therapies Needed for Older Patients With RRMM

Maggie L. Shaw
Relapsed/refractory multiple myeloma (RRMM) remains an incurable hematologic cancer, often resulting in patients treated with several classes of medications—particularly older patients.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo